title: Lapatinib: new opportunities for management of breast cancer.
abstract: Approximately 20% of new diagnosed breast cancers overexpress the human epidermal growth factor receptor 2 (EGFR2), also known as erythroblastic leukemia viral oncogene homolog 2 (ERBB2) protein, as a consequence of ERBB2 gene amplification, resulting in a poor prognosis. Clinical outcome can be substantially improved by ERBB2-targeted therapy. Lapatinib is a potent, orally bioavailable small molecule that reversibly and selectively inhibits epidermal growth factor receptor (EGFR1 or ERBB1) and ERBB2 tyrosine kinases. Lapatinib binds the adenosine triphosphate-binding site of the receptor's intracellular domain to inhibit tumor cell growth. This review summarizes the pharmacology, pharmacokinetics, efficacy, and tolerability of lapatinib, and reviews both Food and Drug Administration-approved and investigational uses of lapatinib in breast cancer therapy. The drug is generally well tolerated in patients, with diarrhea and rashes being the most common (usually mild or moderate) adverse effects. Unlike trastuzumab, lapatinib has infrequent adverse effects on cardiac function. Lapatinib has substantial activity for advanced ERBB2-positive breast cancer, particularly in combination with capecitabine, following progression after anthracyclines, taxanes, and trastuzumab. Lapatinib combined with capecitabine yielded significant improvements in time to progression and response rate compared with capecitabine alone. This drug can also be combined with letrozole for the treatment of postmenopausal women with ERBB2-positive breast cancer, for whom hormonal therapy is indicated. Lapatinib has shown early promise in treatment of central nervous system metastasis and is being further evaluated in various clinical settings.
authors.affiliation: Braman Family Breast Cancer institute, University of Miami Sylvester Comprehensive Cancer Center, USA.
authors.forename: Julia
authors.initials: J
authors.lastname: Liao
authors.affiliation: Braman Family Breast Cancer institute, University of Miami Sylvester Comprehensive Cancer Center, USA.
authors.forename: Michelle
authors.initials: M
authors.lastname: Gallas
authors.affiliation: Braman Family Breast Cancer institute, University of Miami Sylvester Comprehensive Cancer Center, USA ; Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, USA ; Departments of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
authors.forename: Mark
authors.initials: M
authors.lastname: Pegram
authors.affiliation: Braman Family Breast Cancer institute, University of Miami Sylvester Comprehensive Cancer Center, USA ; Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, USA ; Departments of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA ; Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL, USA.
authors.forename: Joyce
authors.initials: J
authors.lastname: Slingerland
keywords: ERBB family; ERBB2; breast cancer; capecitabine; lapatinib; letrozole; trastuzumab